Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-11-21

Clinical Trial Update: Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial results show dupilumab monotherapy used in adults with moderate-to-severe atopic dermatitis; the study has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Dermatitis, Atopic | Phase 3 | Status: COMPLETED | Results posted: 2017-11-21